YMAB 8-K Furnishes Q2 Results; Exhibit 99.1 Press Release and XBRL Data

Rhea-AI Filing Summary

Y-mAbs Therapeutics reported that it has announced its financial results for the quarter ended June 30, 2025 and furnished a related press release as Exhibit 99.1 to this Form 8-K. The filing states that the material furnished, including Exhibit 99.1, is not to be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except by specific reference.

The text of this 8-K does not include any financial metrics or operating results; an Interactive Data File (Inline XBRL) is included as Exhibit 104. Investors must review the attached press release for the actual financial details.

Positive

• Disclosure of quarterly results for the period ended June 30, 2025
• Press release attached as Exhibit 99.1 and Interactive Data File included as Exhibit 104

Negative

• No financial figures, metrics, or explanations are contained in the 8-K text
• Information is explicitly "furnished" not "filed", limiting incorporation and Section 18 liability

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished without in-text financial figures; impact depends on the attached press release.

The Form 8-K notifies the market that Y-mAbs has announced results for the quarter ended June 30, 2025 and attaches the announcement as Exhibit 99.1. Because the filing itself contains no revenue, EPS, cash, or guidance figures, the 8-K alone provides limited information for valuation or short-term trading decisions. The filing also clarifies the press release is "furnished" and not "filed," which affects legal incorporation and Section 18 liability. Until Exhibit 99.1 is reviewed, the filing should be treated as a formal notice rather than a source of metrics.

Corporate Governance Expert

TL;DR: Compliance appears standard — results furnished and XBRL provided; lack of embedded figures reduces immediate materiality.

The company attached the press release as Exhibit 99.1 and an Inline XBRL interactive data file as Exhibit 104, indicating efforts to provide machine-readable disclosures. The explicit statement that the information is "furnished" rather than "filed" is a common legal distinction that limits incorporation into other filings. From a governance and disclosure-process view, the 8-K meets routine disclosure requirements, but it is not materially informative by itself without the contents of the press release.

0001722964false00017229642025-08-082025-08-08

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

​

Date of report (Date of earliest event reported): August 8, 2025

​

Y-MABS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38650		47-4619612
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

​

202 Carnegie Center

Suite 301

Princeton, New Jersey 08540

(Address of principal executive offices) (Zip Code)

​

(646) 885-8505

(Registrant’s telephone number, include area code)

​

N/A

(Former Name or Former Address, if Changed Since Last Report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class:		Trading Symbol		Name of each exchange on which registered:
Common Stock, $0.0001 par value		YMAB		NASDAQ Global Select Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company  ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

​

​

​

Item 2.02. Results of Operations and Financial Condition.

​

On August 8, 2025, Y-mAbs Therapeutics, Inc., announced its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

​

The information furnished pursuant to Item 2.02 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

​

Item 9.01. Financial Statements and Exhibits.

​

(d) Exhibits

​

Exhibit No.		Description
99.1		Press Release, dated August 8, 2025.
104		Interactive Data File (embedded within the Inline XBRL document).

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

	Y-MABS THERAPEUTICS, INC.
Date: August 8, 2025	By:	/s/ Michael Rossi
		Michael Rossi
		President and Chief Executive Officer

​

​

FAQ

What did Y-mAbs (YMAB) announce in this 8-K?

The company announced it has released its financial results for the quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1.

Does the 8-K include financial numbers for YMAB's quarter?

No. The 8-K text does not contain revenue, earnings, cash balances, or other financial metrics; those should be in the attached press release (Exhibit 99.1).

Is the press release considered "filed" with the SEC?

No. The filing states the information, including Exhibit 99.1, is "furnished" and therefore not deemed "filed" for purposes of Section 18 of the Exchange Act.

Is machine-readable data provided?

Yes. An Interactive Data File (Inline XBRL) is included as Exhibit 104 with the filing.

Where can I find the actual financial details mentioned?

The actual financial details are contained in the press release attached as Exhibit 99.1; the 8-K itself contains only the notice that the results were announced.